[Skip to Content]
[Skip to Content Landing]
November 1971

Benign Mucous Membrane Pemphigoid

Author Affiliations

Rochester, Minn

From the Mayo Graduate School of Medicine (University of Minnesota) (Drs. Hardy and Pingree) and the departments of dermatology (Dr. Perry) and ophthalmology (Dr. Kirby), Mayo Clinic and Mayo Foundation, Rochester, Minn.

Arch Dermatol. 1971;104(5):467-475. doi:10.1001/archderm.1971.04000230009002

The clinical and laboratory data on 81 patients with benign mucous membrane pemphigoid (BMMP) seen during the years 1950 through 1968 were reviewed. Mucous-membrane and cutaneous involvements were variable, but the oral mucosa and conjunctivae were eventually involved in approximately 75% of the cases. Scarring was a common complication of mucosal and cutaneous lesions. The most severe sequela was blindness. Of the 81 patients in this series 21 became blind, 17 in both eyes. Systemic administration of corticosteroids, used in 33 cases, was the single treatment of greatest benefit. Daily doses equivalent to 40 mg of prednisone were required initially to retard or arrest the disease. Of the various corticosteroid preparations employed, triamcinolone was the most effective. There were no deaths attributed to BMMP, but one patient died from the side effects of corticosteroid therapy.